Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points

 Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and clinically meaningful improvements across co-primary and key secondary endpoints at week 24 which were sustained through week 52 in adolescent and adult patients with symptomatic and uncontrolled eosinophilic esophagitis (EoE).1,2 

CROSSING evaluated TEZSPIRE 210 mg and 420 mg administered subcutaneously every four weeks. Treatment with TEZSPIRE achieved histologic remission for 64.8% (210 mg dose) and 68.9% (420 mg dose) of patients at week 24, compared to 3.5% of patients on placebo (p<0.001). TEZSPIRE also reduced the frequency and severity of dysphagia symptoms (difficulty swallowing) by 18.8 points (210 mg dose; p=0.049) and 22.0 points (420 mg dose, p<0.001) from baseline vs. 14.7 points on placebo, as measured by the Dysphagia Symptom Questionnaire (DSQ) score, a patient-reported outcome measure.